Q-omics provides the consensus-scored VDAC1P2 profile across patient tissues and cancer cell-line models. VDAC1P2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, VDAC1P2 is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, VDAC1P2 RNA expression shows 16,653 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, BLCA, and ACC as cancer lineages where VDAC1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VDAC1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VDAC1P2 survival associations across molecular data types. VDAC1P2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VDAC1P2 RNA expression–survival associations across cancer types. High VDAC1P2 expression shows unfavorable associations in UVM, LUAD and ACC, but favorable associations in READ, KIRC and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for VDAC1P2 RNA expression.
This table summarizes VDAC1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for VDAC1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VDAC1P2 shows higher tumor expression in BLCA, COAD, LUAD, KIRC, UCEC and LUSC. The BLCA box plot shows higher VDAC1P2 RNA expression in tumor versus normal tissue (log2 FC = +0.349, t-test p < 0.001).
This table shows molecular features associated with VDAC1P2 in patient tissues and cancer cell lines. In patient samples, VDAC1P2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
